SHAREHOLDER ALERT: Morris Kandinov Investigating FFIE, CAPR, COO, and SEMOX; Shareholders are Encouraged to Contact the Firm
03. November 2021 07:30 ET
|
Morris Kandinov, LLP
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Future Intelligent Electric Inc., Capricor...
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
19. Dezember 2019 13:14 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics...
Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
07. November 2019 16:00 ET
|
Capricor Therapeutics, Inc.
Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and Webcast Today at 4:30 p.m....
Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
21. Oktober 2019 09:25 ET
|
Capricor Therapeutics, Inc.
Call Scheduled for Thursday, October 24th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company...